Research Article

Evaluation of Methanol-Dichloromethane Extract of *Stemonocoleus micranthus* Harms (Fabaceae) Stem Bark for Anti-Inflammatory and Immunomodulatory Activities

Florence Nwakaego Mbaogi,¹ Akachukwu Marytheresa Onwuka¹, Sunday Onu,¹ Ikechukwu Emmanuel Peter,¹ Justus Amuche Nweze², and Lilian Eleje Okonta³

¹Department of Pharmacology & Toxicology, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka 410001, Nigeria

²Department of Science Laboratory Technology, Faculty of Physical Sciences, University of Nigeria, Nsukka 410001, Nigeria

³Department of Pharmacognosy and Environmental Medicines, Faculty of Pharmaceutical Sciences, University of Nigeria, Nsukka 410001, Nigeria

Correspondence should be addressed to Akachukwu Marytheresa Onwuka; akachukwu.onwuka@unn.edu.ng

Received 5 January 2020; Revised 11 March 2020; Accepted 13 April 2020; Published 7 May 2020

Academic Editor: Min Li

Copyright © 2020 Florence Nwakaego Mbaogi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Background. The stem bark decoction of *Stemonocoleus micranthus* Harms (Fabaceae) is most widely used traditionally as a remedy for various diseases such as malaria and boil. In this study, the anti-inflammatory and immunomodulatory activities of the methanol-dichloromethane extract (MDE) from the stem bark of the plant in rodents were evaluated. **Methods.** The carrageenan-induced rat paw oedema, cotton pellet-induced granuloma in rat, and xylene-induced ear oedema in mice were used to study the anti-inflammatory activity of methanol-dichloromethane extract of *Stemonocoleus micranthus* (MDESm) (100, 200, and 400 mg/kg). The effects of MDESm (100, 200, and 400 mg/kg) on cyclophosphamide-induced immunosuppression, neutrophil adhesion, carbon clearance, and haematological and biochemical parameters were carried out to study its immunomodulatory activity in mice. **Result.** MDESm (100 mg/kg, p.o.) significantly ($p < 0.05$) inhibited carrageenan-induced oedema by 57.1% at 5th h post-treatment compared with control. At 100 mg/kg, p.o., MDESm significantly ($p < 0.05$) reduced cotton pellet-induced granuloma by 39.28% and nonsignificantly reduced xylene-induced ear oedema by 34.1%. Treatment with MDESm (100 and 400 mg/kg) nonsignificantly abolished the neutropenia caused by cyclophosphamide with a percentage neutrophil reduction of 0 and -14.86%, respectively, while MDESm (200 mg/kg) and levamisole (50 mg/kg) had a nonsignificant reduction in neutrophil count (10.16 and 31.40%), respectively, all compared to the distilled water-treated group with a neutrophil count of -9.82%. MDESm at doses of 100 and 200 mg/kg increased phagocytic index by 0.0447 ± 0.00762 and 0.0466 ± 0.00703 , respectively, although not significantly when compared to the control group with a value of 0.0226 ± 0.02117 . There was a decrease in WBC and lymphocyte counts in MDESm- (200 mg/kg) treated group, suggesting immunosuppressive potential at this dose. MDESm caused a dose-dependent decrease in ALT and core liver enzymes, suggesting a hepatoprotective effect. The acute toxicity test revealed that MDESm is safe in mice with an oral lethal dose (LD_{50}) of >5 g/kg. **Conclusion.** The methanol-dichloromethane extract of *Stemonocoleus micranthus* Harms possesses mild anti-inflammatory and immunomodulatory activities which may be more pronounced upon fractionation and purification. Therefore, more investigations are needed to explore these activities further.

1. Introduction

Inflammation is a broad term, but essentially it is the host defense reactions to tissue injury or infection caused by numerous stimuli such as chemicals, physical trauma as well

as infectious agents. It is triggered by the immune system cells and characterized by dysfunction of the tissues and organs, leading to swelling, heat, redness, and pain [1]. The variations in the levels of immune system cells involved in inflammation have been reported to have consequential

implications in the pathology and physiology (function and symptoms) of various diseases including diabetes, atherosclerosis, obesity, cancer, and fibrosis [2, 3]. Inflammation is one the most insidious causes of many chronic and overlooked diseases; however, the use of anti-inflammatory drugs (such as steroids and/or nonsteroid drugs) for a long time has in many instances resulted in hormonal side effects and damage to the gastric lesions, kidney, and heart, thereby limiting their uses. Most of these drugs help the immune cells to self-regulate as well as to adjust immune responses to adaptive rather than maladaptive levels [4]. In spite of present-day progress in the development of anti-inflammatory therapy, it is still essential to find potent and effective anti-inflammatories, specifically for the treatment of chronic inflammatory disorders.

In modern medicine, natural products from plants have been used tremendously for the development of important therapeutic drugs [5, 6]. Due to side effects and one target-specific action of allopathic drugs, medicinal herbs or plant natural products work in a way that depends on an orchestral approach. There are multitudes of different molecules in a plant that work coactively on targeted components of the complex cellular pathway [5, 7]. For many centuries, a wide variety of biologically active compounds have been sourced from medicinal plants and utilized magnificently either as pure compounds or as crude material for treating various human and animal disease conditions [6].

Stemonocoleus micranthus Harms (Fabaceae) (called Ahianana in Ivory Coast, and Nre and Erhanebeni in Southeast and Edo State, Nigeria, respectively) is an uncommon very large forest tree (up to 45 m high) with leaflets similar to those of *Detarium* species, but with fewer numbers of lateral veins. Its morphology has been previously described [8]. It has a white and hard sapwood and is distributed in the primary forest of southern Nigeria, Congo, eastern Cameroun, Gabon, and Ivory Coast. The stem bark decoction of this plant is most widely used traditionally as remedies for various diseases [9]. Although this plant has not been well investigated, there are reports on its analgesic, narrow-spectrum antibacterial, central nervous system (CNS) depressant, local anesthetic [10], antiulcer [11], antioxidant and hepatoprotective [12], hypolipidemic [13], antimicrobial [14], and antimalarial [15] activities including its use for the treatment of Buruli ulcer lesion in Cameroon [7].

Therefore, the purpose of this research was to evaluate and determine the anti-inflammatory and immunomodulatory activities of *Stemonocoleus micranthus* Harms extract in rats and mice, respectively.

2. Materials and Methods

2.1. Chemicals, Reagents, Solvents, and Drugs. All chemicals used were of analytical grade and include methanol (Sigma-Aldrich, Germany), dichloromethane (Sigma-Aldrich, Germany), distilled water, chloroform, ketamine hydrochloride (Rotex Medical, Germany), xylazine, xylene, normal saline, 0.1% sodium carbonate solution, Leishman's stain, Indian ink, Hayem solution, levamisole (Ecomed

Pharma Ltd, Nigeria), and cyclophosphamide (Kwality Pharma Ltd, India).

2.2. Equipment/Instruments. The equipment and instruments used include milling machine (Lab mill, serial no. 4745, Christy and Norris Ltd., England), electronic animal weighing balance (B. Bran Scientific & Instrument Co. England), analytical weighing balance, Soxhlet apparatus, rotary evaporator (B. Bran Scientific & Instruments Co., England), oven, incubator, photoelectronic colorimeter (Mumbai, India), and visible spectrophotometer (Mumbai, India).

2.3. Experimental Animals. Adult Swiss albino rats (150–200 g) and Swiss albino mice (17–25 g) of both sexes were obtained from the Animal Facility of the Department of Pharmacology and Toxicology, University of Nigeria, Nsukka. Animal experiments were done in compliance with the National Institute of Health Guide for Care and Use of Laboratory Animals (Pub. no. 85–23, revised 1985).

2.4. Collection, Preparation, and Extraction of Plant Material. Fresh *Stemonocoleus micranthus* stem barks were collected from the forest of Orba Nsukka in Udenu Local Government Area of Enugu State, Nigeria, in the month of July. The identification and authentication were done at International Center for Drug Research and Development (InterCEDD), Nsukka, Enugu State, Nigeria, by Mr. Alfred Ozioko. The stem barks were separated from the woody part, sliced into small bits, sun-dried, and pulverized into powder. The bark powder (2.4 kg) was weighed and stored in an airtight container before use. About 2.4 kg of the powdered material was extracted with about 10 L of a 1 : 1 mixture of methanol-dichloromethane by continuous extraction in a Soxhlet extractor. The filtrate was concentrated using a rotary evaporator to obtain methanol-dichloromethane extract of *Stemonocoleus micranthus* (MDESm) (106.28 g). The extract was stored in an amber coloured bottle in a refrigerator at 4°C until its use. Distilled water was the reconstitution solvent for the extract and levamisole.

2.5. Phytochemical Analysis of the Extract. The MDESm was subjected to phytochemical analysis using standard procedures [16, 17].

2.6. Pharmacological Tests

2.6.1. Acute Toxicity Test. The mean oral lethal dose (LD₅₀) of MDESm was estimated in mice using Lorke's method [18].

2.6.2. Carrageenan-Induced Rat Paw Oedema. Twenty-five albino rats were weighed and randomly divided into five groups ($n=5$). Group 1 received oral administration of distilled water (2 ml/kg) and group 2 received ibuprofen (100 mg/kg) while groups 3, 4, and 5 received 100, 200, and 400 mg/kg MDESm, respectively. One hour later, 0.1 ml of

1% w/v carrageenan (phlogistic agent) in normal saline was injected into the subplantar region of the right hind paw of the rats, and the volume of the paw size was measured by water displacement at 0 h and at 1, 2, 3, 4, and 5 h after carrageenan injection [19].

The percent inhibition of oedema was calculated using the following formula [20]:

$$\text{inhibition of oedema (\%)} = \frac{V_c - V_t}{V_c}, \quad (1)$$

where V_c is the mean paw oedema volume of control at each hour and V_t is the mean paw volume of treated animals at each hour.

2.6.3. Xylene-Induced Ear Oedema in Mice. Adult albino mice (20–25 g) were randomly allotted into three groups ($n=5$). Groups 1–3, respectively, received topical administration of 0.05 ml of MDESm (100 mg), ibuprofen (100 mg), and distilled water on the anterior part of the right ear. Thereafter, topical inflammation was instantly induced on the posterior surface of the same ear by application of xylene (50 μ l). The left ear was left untreated. Two hours after induction of inflammation, mice were sacrificed by suffocation with chloroform and both ears removed. Circular discs were punched out of the right (treated) and left (untreated) ear lobes using a cork borer (6 mm diameter) and weighed [21]. The difference in the weight of the discs from the right treated and left untreated ears was calculated and used as a measure of oedema relative to control by using the following equation [22]:

$$\text{inhibition of oedema (\%)} = \left[1 - \left(\frac{R_t - L_t}{R_c - L_c} \right) \right] \times 100, \quad (2)$$

where R_t is the mean weight of right ear plug of treated animals; L_t is the mean weight of left ear plug of treated animals; R_c is the mean weight of right ear plug of control animals; and L_c is the mean weight of left ear plug of control animals.

2.6.4. Cotton Pellet-Induced Granuloma in Rats. Twenty-five albino rats were weighed and randomly divided into five groups ($n=5$). The animals were anaesthetized with ketamine (50 mg/kg, p.o.) and xylazine (10 mg/kg, p.o.) before two sterilized cotton pellets (30 mg each) were surgically implanted subcutaneously on either sides in the lumbar region on the dorsal surface of each rat. After the surgery, the animals were allowed to recover before the groups were, respectively, given MDESm (100, 200, and 400 mg/kg), ibuprofen (100 mg/kg), or distilled water (2 ml/kg) orally once daily for seven days. On the 8th day, the animals were sacrificed with chloroform suffocation. The implanted cotton pellets together with the attached granuloma tissues were surgically removed and dried in an oven at 60°C to a constant weight and the weights recorded. The percentage weight increase of granuloma tissue formed was calculated relative to the control [23].

2.7. Immunomodulatory Study

2.7.1. Cyclophosphamide-Induced Neutropenia Assay. Swiss albino mice were randomly divided into five groups ($n=5$), and the groups, respectively, received oral administration of 1 ml/kg distilled water, 50 mg/kg levamisole, and 100, 200, and 400 mg/kg MDESm, for 10 days. Subsequently, a neutropenic dose of cyclophosphamide (200 mg/kg, s.c.) was injected into the animals on the 10th day (the day labelled as day zero). The total leukocyte (TLC) and differential leukocyte counts (DLC) were calculated on day 0 before injection and on day 3 after injection of cyclophosphamide. Blood samples for the determination of TLC and DLC were collected from the animals through the retro-orbital plexus into heparinized tubes. The percentage TLC and DLC in pretreated (day 0) and treated (day 3) groups were compared with the values of the control group [24].

2.7.2. Neutrophil Adhesion Test. Neutrophil adhesion test was performed based on the method described by Fulzele et al. [25]. Twenty-five albino rats were randomly divided into five groups ($n=5$) and received oral administration of distilled water (1 ml/kg), levamisole (50 mg/kg), and MDESm (100, 200, and 400 mg/kg), respectively, for 10 days. On the 10th day, blood samples were collected from the animals through retro-orbital plexus into heparinized tubes and were analysed for TLC and DLC after slide fixation and staining with Leishman's reagent. After the initial counts, the blood samples were incubated with nylon fibres (80 mg/ml) for 10 min at 37°C. The incubated blood samples were again analysed for TLC and DLC. The percentages of neutrophils in the nylon fibre-treated and nylon fiber-untreated bloods were determined, and the difference was taken as an index of neutrophil adhesion [26, 27]. From the results of DLC, TLC, and neutrophil index, the percent neutrophil adhesion was calculated as follows:

$$\text{neutrophil adhesion (\%)} = \frac{NI_u - NI_t}{NI_u} \times 100, \quad (3)$$

where NI_u is the neutrophil index before incubation with nylon fibres and NI_t is the neutrophil index after incubation with nylon fibres.

2.7.3. Carbon Clearance Test. Phagocytic activity of reticuloendothelial systems (RES) was assayed by the carbon clearance test. In this test, twenty-five albino rats were randomly divided into five groups ($n=5$); group 1 received oral dose of distilled water (1 ml/kg) and group 2 received levamisole (50 mg/kg) while groups 3, 4, and 5 received MDESm (100, 200, and 400 mg/kg), respectively, for 10 days. After 48 h of the last dose, 0.1 ml Indian ink was injected into the animals via the tail vein and blood was withdrawn from the retro-orbital plexus of the animals at 0 min before and 15 min after injection of the ink. The blood samples (50 μ l) were mixed with 4 ml of sodium carbonate solution (0.1%) and the absorbance of the mixture was determined at 660 nm [26, 28]. Phagocytic index, K, which is the rate of carbon

elimination from the reticuloendothelial system, was calculated using the following equation:

$$\text{phagocytic index, } K = \frac{\log OD_1 - \log OD_2}{15}, \quad (4)$$

where OD_1 is the optical density at 0 min and OD_2 is the optical density at 15 min.

2.7.4. Haematological Parameter Assay. Twenty-five albino mice were randomly divided into five groups ($n = 5$). Group 1 received oral dose of distilled water (1 ml/kg) and group 2 received levamisole (50 mg/kg), while groups 3, 4, and 5 received MDESm (100, 200, and 400 mg/kg), respectively, for 10 days. At the end of the treatment, blood samples were collected from the retro-orbital plexus of the rats using heparinized capillary tubes, and the determination of haematological indices was done using standard procedures [29, 30].

(1). Total Leucocyte Count (TLC) Test. This test is also known as the total white blood cell (WBC) count test. The test was carried out by mixing 0.38 ml of 1% glacial acetic acid (the WBC diluting fluid) with 0.02 ml of blood in a test tube, and the resultant mixture was counted with the improved Neubauer counting chamber using $\times 40$ magnification lens. The four corner squares of the central square were counted, and the number of cells (cells/ μ l) counted was recorded.

(2). Differential Leucocyte Count (DLC) Test. The differential leucocyte count test was carried out by fixing the blood on a slide and staining with Leishman's stain. The slides were kept for 8 min before the excess stain was washed off with a sufficient quantity of water and were air-dried. Oil immersion was added on the slides which were subsequently examined under a light microscope using $\times 100$ magnifications. The percentage neutrophils (cells/ μ l) were determined.

(3). Red Blood Cell Count Test. Blood (20 μ l) was mixed with 4 ml of Hayem's solution (RBC diluting fluid), and the resultant mixture was counted with the improved Neubauer counting chamber as described for TLC above using $\times 40$ magnification.

(4). Platelet Determination. The platelet count test was carried out by mixing 0.38 ml of filtered ammonium oxalate (platelet diluting fluid) with 0.02 ml of blood in a test tube, and the mixture was counted with the improved Neubauer counting chamber using $\times 40$ magnification. The platelets (cells/ μ l) were counted only on the 16 squares of one square.

(5). Estimation of the Haemoglobin (Hb) Content. Cyanmethemoglobin method was adopted. A 4 ml of Drabkin's solution (Hb diluting fluid) was mixed with 0.02 ml of blood in a test tube, allowed to stand for 5 min, and viewed against the blank at a wavelength of 540 nm with a photoelectronic colorimeter. The observed values (g/dl) were read off on a calibration curve.

2.7.5. Assessment of Biochemical Parameters. Twenty-five albino rats were randomly divided into five groups ($n = 5$) and received oral doses of distilled water (1 ml/kg), levamisole (50 mg/kg), and MDESm (100, 200, and 400 mg/kg), respectively, for 10 days. At the end of the treatment, blood samples were collected from the retro-orbital plexus using nonheparinized capillary tubes, and biochemical parameters (liver enzymes) were assayed following the procedures outlined by Kind and King [31, 32].

(1) Serum Alanine Transaminase (ALT) and Aspartate Transaminase (AST) Determination. A colorimetric method was used. The two procedures are the same but with their respective substrates. A volume (0.5 ml) of ALT substrate solution (200 mmol/L DL-alanine and 2 mmol/L α -ketoglutarate) or AST substrate solution (200 mmol/L L-aspartate (in Tris buffer, pH 7.4) and 2 mmol/L ketoglutarate) was added into five test tubes which were preincubated for 30 min at 37°C. Afterwards, 0.1 ml of serum sample was added to the test tubes which were incubated for 30 min at 37°C. Later, 0.5 ml of the colour developer (1 mmol/L 2, 4-dinitrophenylhydrazine) was added to the sample and the standard solution (1.2 mmol/L pyruvate) test tubes. The tubes were allowed to stand for 20 min at room temperature. Thereafter, 5 ml of 4 N NaOH working solution was added to the test tubes which were then allowed to stand for 15 min at room temperature. The absorbance of both test samples and standard solutions were read at 505 nm against deionized water blank. The experiment was repeated for all the groups. The ALT or AST activity of the samples was obtained by interpolating the absorbance obtained for the samples in the calibration curve made from the standard. The results were expressed in international unit per liter (IU/L) as shown in the following equation:

$$\text{ALT (IU/L)} = \frac{\text{Abs}_{\text{sample}} - \text{Abs}_{\text{standard}}}{0.059}, \quad (5)$$

$$\text{AST I (U/L)} = \frac{\text{Abs}_{\text{sample}} - \text{Abs}_{\text{standard}}}{0.002}.$$

(2). Serum Alkaline Phosphatase (ALP) Determination. The test was carried out by adding 0.05 ml of serum to 0.5 ml of buffer (pH 10) (premixed with 0.5 ml substrate (M/100 Na_2 -phenyl phosphate) and warmed at 37°C for 3 min) in a tube. Then, 0.8 ml of N/2 NaOH was added followed by 1.2 ml of M/2 NaHCO_3 . Then, 1 ml of 0.6% aminoantipyrine was added and mixed before the addition of 1 ml of 2.4% $\text{K}_3\text{Fe}(\text{CN})_6$. The resultant mixture was read at a wavelength of 405 nm with a photoelectronic colorimeter. Reading was repeated after 1, 2, and 3 min. Alkaline phosphatase activity (IU/L) was estimated using the following formula:

$$\text{alkaline phosphatase (IU/L)} = \frac{\text{Abs}_{\text{sample}} - \text{Abs}_{\text{control}}}{\text{Abs}_{\text{standard}} - \text{Abs}_{\text{blank}}} \times 30. \quad (6)$$

2.8. Statistical Analysis. The statistical analyses of data obtained were done by one-way analysis of variance (ANOVA) and subjected to Dunnett's post hoc tests. Data were presented as mean $\pm$ SEM and significant differences accepted at $p < 0.05$.

3. Results

3.1. Extractive Yield and Phytochemical Screening. The extraction process yielded 106.28 g (4.4% w/w) of MDESm. The phytochemical analysis of MDESm showed that the plant extract was rich in alkaloids, glycosides, flavonoids, reducing sugars, carbohydrates, steroids, terpenoids, tannins, fats and oil, and proteins (Table 1).

3.2. Acute Toxicity Test. The acute toxicity test of MDESm in mice showed no death or sign of acute intoxication after 24 h observation period in both stages of the test. The LD₅₀ was estimated to be above 5 g/kg.

3.3. Carrageenan-Induced Rat Paw and Xylene-Induced Ear Oedema in Mice. The result of this test showed that MDESm exhibited a non-dose-dependent rat paw oedema reduction with 100 mg/kg causing a significant ($p < 0.05$) oedema reduction from the 3rd hour up till the 5th hour in comparison with control (Table 2). The percentage oedema reduction at this dose is somehow comparable to that of ibuprofen at these hours even though the reduction caused by ibuprofen started from the 2nd hour. From the area under the curve (AUC) values, the global oedema reduction caused by these treatments follows the same pattern as seen in the percentage oedema reduction with MDESm (100 mg/kg) having the lowest area among the other doses of the extract. The order of increasing AUC (mlh) values for the treatments is as follows: 1.270 (ibuprofen) < 1.890 (MDESm, 100 mg/kg) < 2.820 (MDESm, 200 mg/kg) < 3.480 (MDESm, 400 mg/kg) < 3.490 (control) (Table 2).

Topical application of MDESm (100 mg) reduced xylene-induced ear oedema by 5.4 ± 0.927 (34.1%) although not significantly; ibuprofen (100 mg) significantly ($p < 0.05$) reduced it by 2.60 ± 1.030 (51.0%) when compared to control (8.2 ± 0.583) (Figure 1).

3.4. Effect of MDESm on Cotton Pellet-Induced Granuloma. The weight of the granuloma tissue for the control group of animals was found to be 0.28 ± 0.02 mg (Table 3). Treatment with the different concentrations of MDESm reduced the granuloma tissue formed and only MDESm (100 mg/kg) significantly ($p < 0.05$) reduced the weight by 39.28% which was slightly greater than the reduction (32.14%) caused by ibuprofen (Table 3).

3.5. Effect of MDESm on Cyclophosphamide-Induced Neutropenia. The administration of cyclophosphamide (200 mg/kg) caused a reduction in neutrophil and total leucocyte counts in most of the groups. The percentage reduction of TLC in the MDESm-treated groups when

TABLE 1: List of compounds present in MDESm.

Constituents	Relative presence
Alkaloids	+
Carbohydrates	++++
Fats and oils	++
Flavonoids	++++
Glycosides	++++
Proteins	+++
Reducing sugars	+++
Resins	—
Saponins	++
Steroids	++
Tannins	++++
Terpenoids	+

— = not present; + = present in small concentration; ++ = present in moderate concentration; +++ = present in high concentration; ++++ = abundantly present; MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*.

compared to the control group increased with increasing dose of the extract as follows: 100 mg/kg (68.32%), 200 mg/kg (75.68%), and 400 mg/kg (83.12%), which were lower than the significant ($p < 0.05$) reduction (95.34%) observed in the levamisole-treated group. However, the reduction in neutrophil count did not follow the same pattern as observed in the TLC. The levamisole-treated group recorded the highest percentage reduction of 31.4% followed by MDESm 200 mg/kg with 10.16% while there was no reduction in MDESm 100 mg/kg which had 0%, but there was an increase in MDESm 400 mg/kg group with a negative percentage value of -14.6%, all in comparison to control (Table 4).

3.6. Effect of MDESm on Neutrophil Adhesion. Incubation of blood with nylon fibres caused a decrease in the neutrophil counts due to adhesion of neutrophils to the fibres. There was a dose-dependent increase in the percentage of neutrophils that adhered to the nylon fibres in the MDESm-treated groups (100 mg/kg (41.1%), 200 mg/kg (45.04%), and 400 mg/kg (45.78%)); these values were comparable to that of levamisole which had a higher percentage (46.78%) of adhered neutrophils but were significantly ($p < 0.05$) lower than that of control (64.5%) (Table 5).

3.7. Effect of MDESm on Carbon Clearance. The carbon clearance method was used to study the *in vivo* phagocytic activity of MDESm. The MDESm 100 and 200 mg/kg caused higher phagocytosis with phagocytic indices of 0.0447 ± 0.00762 and 0.0466 ± 0.00703 , respectively, more than that of MDESm 400 mg/kg with a phagocytic index of 0.0096 ± 0.00903 and levamisole (0.0333 ± 0.01794). These values were not significant when compared to the value (0.0226 ± 0.02117) for control (Table 6).

3.8. Effect of MDESm on Haematological Parameters. Administration of MDESm (100, 200, and 400 mg/kg) in rats for 10 days did not have any significant effect on the haematological indices of the animals in comparison with the control group (Table 7).

TABLE 2: Effect of MDESm on carrageenan-induced rat paw oedema.

Treatment	Dose (mg/kg)	1 h	2 h	3 h	4 h	5 h	AUC (mlh)
Control (dist. water)	2 ml/kg	0.42 ± 0.10	0.76 ± 0.074	0.82 ± 0.047	1.00 ± 0.063	0.98 ± 0.058	3.490 ± 0.245
Ibuprofen	100	0.16 ± 0.07 (61.9)	0.28 ± 0.09* (63.2)	0.30 ± 0.12* (63.4)	0.36 ± 0.12* (64.0)	0.33 ± 0.11* (66.32)	1.270 ± 0.345
MDESm	100	0.24 ± 0.02 (42.9)	0.52 ± 0.09 (31.6)	0.40 ± 0.14* (51.2)	0.52 ± 0.15* (48.0)	0.42 ± 0.14* (57.1)	1.890 ± 0.392
MDESm	200	0.30 ± 0.09 (28.6)	0.66 ± 0.11 (13.2)	0.78 ± 0.14 (4.9)	0.70 ± 0.13 (30.0)	0.76 ± 0.12 (22.5)	2.820 ± 0.396
MDESm	400	0.34 ± 0.07 (19.1)	0.75 ± 0.15 (1.3)	0.94 ± 0.06 (-14.6)	0.98 ± 0.04 (2.0)	0.92 ± 0.05 (6.1)	3.480 ± 0.289

Mean ± SEM, $n = 5$; $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc test); values in parentheses are percentage oedema reduction compared to control. MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*; AUC = area under the curve.

FIGURE 1: Effect of MDESm on xylene-induced ear oedema in mice ($n = 5$); values were expressed as mean ± SEM. * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc tests). MDESm: methanol-dichloromethane extract of *Stemonocoleus micranthus*.

TABLE 3: Effect of MDESm on cotton pellet-induced granuloma in rats.

Treatment	Dose (mg/kg)	Mean weight (mg)	% reduction
Control (dist. water)	2 (ml/kg)	0.28 ± 0.02	—
Ibuprofen	100	0.19 ± 0.032*	32.14
MDESm	100	0.17 ± 0.016*	39.28
MDESm	200	0.23 ± 0.029	17.85
MDESm	400	0.23 ± 0.012	17.85

Mean ± SEM, $n = 5$; * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc tests). MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*.

3.9. Effect of MDESm on Biochemical Parameters in Rats. From Table 8, there were a dose-dependent decrease in ALT of rats treated with MDESm (100, 200, and 400 mg/kg) and a significant ($p < 0.05$) increase in AST caused by 400 mg/kg which was greater than that of levamisole (55.4 ± 9.21) and other doses of the extract (100 mg/kg (49.3 ± 13.33) and 200 mg/kg (45.6 ± 3.04)) in comparison with control (48.2 ± 5.60). However, MDESm at all doses caused a significant ($p < 0.05$) reduction in ALP compared to control.

4. Discussion

In this study, the anti-inflammatory and immunomodulatory activities of *Stemonocoleus micranthus* Harms (Fabaceae) stem bark extract were investigated using different experimental models.

Preliminary screening for the presence of secondary metabolites in plant extract is an important step for quality control and standardization. This study has shown that MDESm is rich in active metabolites such as alkaloids, saponins, flavonoids, steroids, tannins, and terpenoids as previously reported [11, 12], which may be responsible for its mild anti-inflammatory and immunomodulatory activities. It has been reported that flavonoids possess many pharmacological properties such as immunomodulatory, anti-inflammatory, and antioxidant activities [33–36]. The acute toxicity test showed that MDESm was safe above the dose of 5000 mg/kg, indicating high degree of safety from acute intoxication.

The *in vivo* anti-inflammatory activity was investigated using carrageenan-induced rat paw oedema. Carrageenan-induced rat paw oedema is largely associated with the production of several inflammatory mediators such as histamine, prostaglandins, kinins, nitric oxide (NO), and cytokines [37]. The development of carrageenan-induced paw oedema is biphasic in nature [38]. The first phase (1–2 h after carrageenan injection) is mediated by histamine, serotonin, and bradykinins released from mast cells while the second phase (3–5 h after carrageenan injection) is connected with the release of arachidonate metabolites such as leukotrienes and cytokines [39–41]. The groups pretreated with MDESm (100 mg/kg, p.o.) significantly reduced rat paw oedema from the 3rd to the 5th h post-carrageenan injection, compared with the control group showing that its anti-inflammatory activity may be at much lower doses.

The acute anti-inflammatory activity of any agent can be estimated by xylene-induced ear oedema test [22]. Xylene is a phlogistic agent that increases oedema formation by initiating the actions of mediators such as serotonin, histamine, bradykinin, and prostaglandins causing inflammation [42]. Findings from this test indicate that MDESm at a dose of 100 mg had mild anti-inflammatory activity as it reduced the xylene-induced ear oedema in the treated mice although not significantly.

TABLE 4: Effect of MDESm on cyclophosphamide-induced neutropenia in mice.

Treatment	Dose (mg/kg)	Total leucocyte count (cells/mm ³)		Reduction in cell number after cyclophosphamide treatment (%)	Total neutrophils (cells/mm ³)		Reduction in cell number after cyclophosphamide treatment (%)
		Before	After		Before	After	
Control (dist. water)	1 (ml/kg)	9120 ± 1563	1180 ± 162	7940 ± 1573 (87.06)	22.4 ± 3.74	24.6 ± 2.80	-2.2 ± 1.88 (-9.82)
Levamisole	50	15880 ± 3172	740 ± 163	15140 ± 3315* (95.34)	21.0 ± 3.79	14.4 ± 2.15	6.6 ± 1.80 (31.40)
MDESm	100	10575 ± 1003	3350 ± 212	7225 ± 3078 (68.32)	18.7 ± 3.42	18.7 ± 3.06	0.0 ± 5.11 (0.00)
MDESm	200	7980 ± 1285	1940 ± 821	6040 ± 1557 (75.68)	23.6 ± 3.50	21.2 ± 3.12	2.2 ± 4.03 (10.16)
MDESm	400	9925 ± 726	1675 ± 342	8250 ± 1034 (83.12)	22.2 ± 3.81	25.5 ± 2.90	-3.3 ± 5.55 (-14.86)

Mean ± SEM; $n = 5$; * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc test). MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*.

TABLE 5: Effect of MDESm on neutrophil index and neutrophil adhesion in rats.

Treatment	Dose (mg/kg)	TLC (cells/mm ³) (x)		% neutrophil (y)		Neutrophil adhesion (%)		Neutrophil index (xy)
		UnB	FTB	UnB	FTB	UnB	FTB	
Control (dist. water)	1 (ml/kg)	11128 ± 1593	6180 ± 1194	24.2 ± 3.32	15.0 ± 2.19	272000 ± 51722	96560 ± 25850	64.50
Levamisole	50	8040 ± 1073	6500 ± 1121	19.6 ± 1.91	12.4 ± 1.12	156280 ± 20293	83160 ± 20426	46.78
MDESm	100	13900 ± 1100	11475 ± 891*	28.8 ± 1.49	20.5 ± 70	401000 ± 43287*	236050 ± 27009	41.13*
MDESm	200	15440 ± 3068	11140 ± 1573*	24.0 ± 3.98	18.2 ± 3.69	346400 ± 54386	190380 ± 34520	45.04*
MDESm	400	9560 ± 927	7700 ± 559	23.0 ± 3.82	15.0 ± 3.17	210880 ± 17759	114280 ± 25910	45.80

Mean ± SEM, $n = 5$; * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc test). UnB: untreated blood; FTB: nylon fibre-treated blood; MDESm: methanol-dichloromethane extract of *Stemonocoleus micranthus*.

TABLE 6: Effect of MDESm on phagocytic index in carbon clearance assay in rats.

Treatment	Dose (mg/kg)	Phagocytic index
Control (dist. water)	—	0.0226 ± 0.02117
Levamisole	50	0.0333 ± 0.01794
MDESm	100	0.0447 ± 0.00762
MDESm	200	0.0466 ± 0.00703
MDESm	400	0.0096 ± 0.00903

Mean ± SEM, $n = 5$; * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc tests). MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*.

TABLE 7: Effect of MDESm on haematological parameters in mice.

Treatment	Dose (mg/kg)	WBC (cells/ μ L)	Hb (g/dL)	Platelets (cells/ μ L)	Neutrophil (cells/ μ L)	Lymphocytes (cells/ μ L)
Control (dist. water)	—	9120 ± 1563	13.38 ± 0.31	222000 ± 48104	22.4 ± 3.74	77.6 ± 3.74
Levamisole	50	15880 ± 3172*	13.46 ± 0.44	388000 ± 77549	21.0 ± 3.79	79.0 ± 3.79
MDESm	100	10575 ± 1003	11.90 ± 0.40	255000 ± 71821	18.7 ± 3.42	81.3 ± 3.42
MDESm	200	7980 ± 1285	13.90 ± 0.85	200000 ± 35777	23.6 ± 3.50	76.8 ± 3.73
MDESm	400	9925 ± 726	13.49 ± 0.68	217500 ± 51700	22.2 ± 3.81	77.5 ± 3.81

Mean ± SEM, $n = 5$; * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc test). MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*.

TABLE 8: Effect of MDESm on biochemical parameters in rats.

Treatment	Dose (mg/kg)	AST (IU/L)	ALT (IU/L)	ALP (IU/L)
Control (dist. water)	—	48.2 ± 5.60	22.7 ± 3.22	40.7 ± 7.98
Levamisole	50	55.4 ± 9.21	24.2 ± 3.18	46.2 ± 8.64
MDESm	100	49.3 ± 13.33	19.3 ± 2.02*	21.6 ± 13.90*
MDESm	200	45.6 ± 3.04	15.8 ± 2.57*	15.8 ± 9.89*
MDESm	400	59.0 ± 11.32*	13.0 ± 5.70	37.6 ± 10.00*

Mean ± SEM, $n = 5$; * $p < 0.05$ compared to control (one-way ANOVA; Dunnett's post hoc test). MDESm = methanol-dichloromethane extract of *Stemonocoleus micranthus*; ALT = alanine transaminase; ALP = alkaline phosphatase; AST = aspartate transaminase.

Cotton pellet induced-granuloma model is used to assess the effect of extract in chronic inflammation [43]. It is used to evaluate the transudative and proliferative components of chronic inflammation [44, 45]. Several herbs have been reported to interfere with the synthetic pathway of proinflammatory mediators responsible for chronic inflammation by inhibition of lipoxygenase which is an important enzyme in arachidonic acid pathway [46]. However, the weight of granuloma tissue is determined by the amount of granuloma deposited on the cotton pellets together with the fluid absorbed. The weight of wet cotton pellets correlates with exudative material and weight of the dry pellets correlates with the amount of granuloma tissue deposited [47, 48]. MDES_m at a dose of 100 mg/kg showed a significant ($p < 0.05$) decrease in the granuloma tissue deposited on the cotton compared to control, with percentage reduction of granuloma tissue slightly greater than that of ibuprofen. With increasing doses of MDES_m, there was a gradual increase in the weight of deposited granuloma tissue, indicating that it is more effective at a lower dose. In other words, MDES_m inhibited chronic inflammation in a non-dose-dependent manner.

In experimental animals, cyclophosphamide is usually used to induce myeloid cell suppression. As an alkylating agent, it functions as an immunosuppressive agent by causing alkylation of DNA, in turn by interfering in DNA synthesis and function [49]. MDES_m at a high dose (400 mg/kg, p.o.) abolished the cyclophosphamide-induced neutropenia, suggesting that it may be affecting the hemopoietic system by causing immunostimulation. The activation of macrophages, which release a number of mediators including colony-stimulating factor and interleukin, could be the way cyclophosphamide-induced neutropenia may be prevented [50]. Neutrophil and monocytes are key players in innate immune response, and the results of this study show that MDES_m strengthens the immune system.

The adhesion of neutrophil to nylon fibres indicates the migration of the immune cells in the blood vessels and the number of neutrophils reaching the site of inflammation [50]. MDES_m and levamisole drug did not increase significantly the amount of neutrophils adhered to the nylon fibre compared to the control group. Hence, it can be inferred that MDES_m did not cause appreciable stimulation of neutrophils towards the site of inflammation which may suggest weak immunostimulatory potential, although its immunostimulation increases with increasing dose. Determination of the performance of the reticuloendothelial system and its granulopoietic activity is based on the rate of carbon clearance [51]. Thus, the quicker removal of carbon particles from the blood is related to the rise in phagocytic activity. The MDES_m at lower doses enhanced the phagocytic function by clearing the carbon particle more than levamisole which is a standard immunostimulatory agent. However, this suggests its potential to stimulate the reticuloendothelial system.

The hematopoietic stem cells in the bone marrow are the progenitor of most of the immune system cells. It is in this microenvironment that the site of antigen-dependent differentiation of B-lymphocytes is located [50]. Treatment of

mice with MDES_m for 10 days did not have any significant increase or decrease in their haematological parameters compared to the control group, although at intermediate dose, there was a slight reduction in WBC which may suggest mild immunosuppression at that dose.

Some of the most sensitive markers of hepatocellular injury are ALT and AST, and their elevation in serum is indicative of cellular leakage and loss of the functional integrity of cell membranes in the liver [52]. In this study, the increase in AST which may be from other sources apart from liver and a dose-dependent decrease in ALT after MDES_m administration indicated mild deterioration and non-deleterious effect, respectively, on the cellular integrity and status of hepatic cells. ALP is a membrane-bound enzyme involved in active transport across the capillary wall [52]. The observed decrease in ALP activity in the MDES_m-treated groups in comparison with the control group is also an indication of hepatoprotection. Overall, the positive effect of MDES_m on biochemical parameters is in tandem with the findings of the previous study on the hepatoprotective potentials of this extract against CCl₄-induced oxidative liver damage [12].

5. Conclusion

The observed non-dose-dependent and mild anti-inflammatory and immunomodulatory activities (which may increase with fractionation) of the methanol-dichloromethane stem bark extract of *Stemonocoleus micranthus* Harms seem to support the use of this plant in the treatment of various diseases and metabolic disorders. These activities may largely be as a result of single or combined effects of bioactive compounds present in the plant. However, further investigation is required to isolate the phytoconstituents responsible for the observed activities and possibly elucidate its mechanism of anti-inflammatory and immunomodulatory potential.

Data Availability

The experimental data obtained from various rat models used to support the findings of this study are available from the corresponding author upon request.

Conflicts of Interest

The authors declare no conflicts of interest.

References

- [1] A. Rübsam, S. Parikh, and P. Fort, "Role of inflammation in diabetic retinopathy," *International Journal of Molecular Sciences*, vol. 19, no. 4, p. 942, 2018.
- [2] A. R. Saltiel and J. M. Olefsky, "Inflammatory mechanisms linking obesity and metabolic disease," *Journal of Clinical Investigation*, vol. 127, no. 1, pp. 1–4, 2017.
- [3] M.-Y. Wu, C.-J. Li, M.-F. Hou, and P.-Y. Chu, "New insights into the role of inflammation in the pathogenesis of atherosclerosis," *International Journal of Molecular Sciences*, vol. 18, no. 10, p. 2034, 2017.

- [4] M. Wehling, "Non-steroidal anti-inflammatory drug use in chronic pain conditions with special emphasis on the elderly and patients with relevant comorbidities: management and mitigation of risks and adverse effects," *European Journal of Clinical Pharmacology*, vol. 70, no. 10, pp. 1159–1172, 2014.
- [5] S. Kumar, B. S. Bajwa, S. Kuldeep, and A. N. Kalia, "Anti-inflammatory activity of herbal plants: a review," *International Journal of Advances in Pharmacy, Biology and Chemistry*, vol. 2, no. 2, pp. 272–281, 2013.
- [6] A. G. Atanasov, B. Waltenberger, E.-M. Pferschy-Wenzig et al., "Discovery and resupply of pharmacologically active plant-derived natural products: a review," *Biotechnology Advances*, vol. 33, no. 8, pp. 1582–1614, 2015.
- [7] A. Andreoli, F. Mou, J. C. Minyem et al., "Complete healing of a laboratory-confirmed Buruli ulcer lesion after receiving only herbal household remedies," *PLoS Neglected Tropical Diseases*, vol. 9, no. 11, Article ID e0004102, 2015.
- [8] H. Banks and P. Gasson, "Pollen morphology and wood anatomy of the group (Leguminosae, Caesalpinioideae, Detarieae)," *Botanical Journal of the Linnean Society*, vol. 134, no. 1-2, pp. 19–59, 2000.
- [9] I. P. Udeozo, A. N. Eboatu, N. L. Umedum, N. H. Okoye, and I. H. Kelle, "The effect of ignition time on fifty-two selected Nigerian timbers," *Research Journal of Pharmaceutical, Biological and Chemical Sciences*, vol. 5, no. 2, pp. 847–851, 2014.
- [10] A. O. Anaga, K. F. Chah, M. K. Tchimine, I. C. Udeani, N. Anaele, and P. Akpa, "Investigation of the methanol extract of *Stemonocoleus micranthus* for pharmacological activities," *Nigerian Journal of Experimental and Applied Biology*, vol. 11, no. 1, pp. 97–107, 2010.
- [11] C. C. Ezea, C. T. Nnamdi-Okenwa, C. O. Ezugwu, F. C. Anowi, and S. C. Ezea, "Investigation into the anti-ulcer activity of the methanol extract of *Stemonocoleus micranthus* Harms, bark (fam: leguminosae)," *World Journal of Pharmaceutical Research*, vol. 3, no. 3, pp. 3669–3675, 2014.
- [12] F. N. Mbaoji, A. C. Ezike, C. S. Nworu, C. A. Onyeto, and I. A. Nwabunike, "Antioxidant and hepatoprotective potentials of *Stemonocoleus micranthus* Harms. (Fabaceae) stem bark extract," *International Journal of Pharmacy and Pharmaceutical Sciences*, vol. 8, no. 7, pp. 47–51, 2016.
- [13] F. N. Mbaoji, A. C. Ezike, C. S. Nworu et al., "Sub-chronic effect of methanol-dichloromethane stem bark extract of *Stemonocoleus micranthus* Harms. (Fabaceae) on lipid profile and histology of liver and kidney of rats," *Journal of Pharmacognosy and Natural Product*, vol. 3, no. 2, pp. 1–6, 2017.
- [14] M. K. Tchimine, K. F. Chah, N. Anaele, C. O. Okunji, and M. M. Iwu, "Antimicrobial activity of crude extract, fractions and isolated compound from *Stemonocoleus micranthus*," *International Journal of Microbiological Research*, vol. 9, no. 3, pp. 70–72, 2018.
- [15] C. I. Orabueze, D. A. Ota, and H. A. Coker, "Antimalarial potentials of *Stemonocoleus micranthus* Harms (leguminosae) stem bark in *Plasmodium berghei* infected mice," *Journal of Traditional and Complementary Medicine*, vol. 10, no. 1, pp. 70–78, 2019.
- [16] R. Price, "Phytochemical methods-a guide to modern techniques of plant analysis," *Physiological Plant Pathology*, vol. 27, no. 2, pp. 255–256, 1985.
- [17] Paterson and J. Harborne, "Phytochemical methods," in *A Guide to Modern Techniques of Plant Analysis*, Chapman & Hall, London, UK, 1988.
- [18] D. Lorke, "A new approach to practical acute toxicity testing," *Archives of Toxicology*, vol. 54, no. 4, pp. 275–287, 1983.
- [19] C. A. Winter, E. A. Risley, and G. W. Nuss, "Carrageenin-induced edema in hind paw of the rat as an assay for anti-inflammatory drugs," *Experimental Biology and Medicine*, vol. 111, no. 3, pp. 544–547, 1962.
- [20] M. M. Begum, A. Islam, R. Begum et al., "Ethnopharmacological inspections of organic extract of *Oroxylum indicum* in rat models: a promising natural gift," *Evidence-Based Complementary and Alternative Medicine*, vol. 2019, Article ID 1562038, 13 pages, 2019.
- [21] A. H. Atta and A. Alkofahi, "Anti-nociceptive and anti-inflammatory effects of some Jordanian medicinal plant extracts," *Journal of Ethnopharmacology*, vol. 60, no. 2, pp. 117–124, 1998.
- [22] A. Tubaro, P. Dri, G. Delbello, C. Zilli, and L. R. Della, "The croton oil ear test revisited," *Agents Actions*, vol. 17, pp. 347–349, 1985.
- [23] J. S. Mossa, S. Rafatullah, A. M. Galal, and M. A. Al-Yahya, "Pharmacological studies of rhus retinorrhoea," *International Journal of Pharmacognosy*, vol. 33, no. 3, pp. 242–246, 1995.
- [24] U. Tiwari, B. Rastogi, P. Singh, D. K. Saraf, and S. P. Vyas, "Immunomodulatory effects of aqueous extract of *Tridax procumbens* in experimental animals," *Journal of Ethnopharmacology*, vol. 92, no. 1, pp. 113–119, 2004.
- [25] S. V. Fulzele, P. M. Satturwar, S. B. Joshi, and A. K. Dorle, "Studies on the immunomodulatory activity of an herbal formulation," *Indian Drugs*, vol. 39, no. 7, pp. 364–367, 2002.
- [26] A. B. Gokhale, A. S. Damre, and M. N. Saraf, "Investigations into the immunomodulatory activity of *Argyrea speciosa*," *Journal of Ethnopharmacology*, vol. 84, no. 1, pp. 109–114, 2003.
- [27] U. A. Shinde, A. S. Phadke, A. M. Nair, A. A. Mungantiwar, V. J. Dikshit, and M. N. Saraf, "Preliminary studies on the immunomodulatory activity of *Cedrus deodara* wood oil," *Fitoterapia*, vol. 70, no. 4, pp. 333–339, 1999.
- [28] M. G. Jayathirtha and S. H. Mishra, "Preliminary immunomodulatory activities of methanol extracts of *Eclipta alba* and *Centella asiatica*," *Phytomedicine*, vol. 11, no. 4, pp. 361–365, 2004.
- [29] O. B. Adewale, A. Onasanya, S. O. Anadozie et al., "Evaluation of acute and subacute toxicity of aqueous extract of *Crassocephalum rubens* leaves in rats," *Journal of Ethnopharmacology*, vol. 188, pp. 153–158, 2016.
- [30] A. B. Antai, O. E. Ofem, D. E. Ikpi, S. Ukafia, and E. A. Agiang, "Phytochemistry and some haematological changes following oral administration of ethanolic root extract of *Gonglonema latifolium* in rats," *Nigerian Journal of Physiological Sciences*, vol. 24, no. 1, pp. 79–83, 2009.
- [31] P. R. N. Kind and E. J. King, "Estimation of plasma phosphatase by determination of hydrolysed phenol with aminoantipyrine," *Journal of Clinical Pathology*, vol. 7, no. 4, pp. 322–326, 1954.
- [32] S. Reitman and S. Frankel, "A colorimetric method for the determination of serum glutamic oxalacetic and glutamic pyruvic transaminases," *American Journal of Clinical Pathology*, vol. 28, no. 1, pp. 56–63, 1957.
- [33] M. T. L. Lelpo, A. Basile, R. Miranda et al., "Immunopharmacological properties of flavonoids," *Phytotherapy*, vol. 71, pp. S101–S109, 2000.
- [34] L.-C. Chiang, L. T. Ng, W. Chiang, M.-Y. Chang, and C.-C. Lin, "Immunomodulatory activities of flavonoids, monoterpenoids, triterpenoids, iridoids glycosides and phenolic compounds of plantago species," *Planta Medica*, vol. 69, no. 7, pp. 600–604, 2003.

- [35] M. Zeinali, S. A. Rezaee, and H. Hosseinzadeh, "An overview on immunoregulatory and anti-inflammatory properties of chrysin and flavonoids substances," *Biomedicine & Pharmacotherapy*, vol. 92, pp. 998–1009, 2017.
- [36] A. Hosseinzade, O. Sadeghi, A. N. Biregain, S. Soukhtehzari, G. S. Brandt, and A. Esmailzadeh, "Immunomodulatory effects of flavonoids: possible induction of T CD₄⁺ regulatory cells through suppression of mTOR pathway signalling activity," *Frontier in Immunology*, vol. 10, p. 51, 2019.
- [37] N. Yahfoufi, N. Alsadi, M. Jambi, and C. Matar, "The immunomodulatory and anti-inflammatory role of polyphenols," *Nutrients*, vol. 10, no. 11, p. 1618, 2018.
- [38] A. Alemu, W. Tamiru, T. Nedi, and W. Shibeshi, "Analgesic and anti-inflammatory effects of 80% methanol extract of *Leonotis ocymifolia* (burm. F.) iwarsson leaves in rodent models," *Evidence-Based Complementary and Alternative Medicines*, vol. 2018, Article ID 1614793, 8 pages, 2018.
- [39] V. Suba, T. Murugesan, R. Kumaravelrajan, S. C. Mandal, and B. P. Saha, "Antiinflammatory, analgesic and antiperoxidative efficacy of *Barleria lupulina* Lindl. extract," *Phytotherapy Research*, vol. 19, no. 8, pp. 695–699, 2005.
- [40] C. Marrassini, C. Acevedo, J. Miño, G. Ferraro, and S. Gorzalczany, "Evaluation of antinociceptive, anti-inflammatory activities and phytochemical analysis of aerial parts of *Urtica urens* L.," *Phytotherapy Research*, vol. 24, no. 12, pp. 1807–1812, 2010.
- [41] H. K. Solanki, D. A. Shah, C. A. Patel, P. M. Maheriya, and C. A. Patel, "Evaluation of anti-inflammatory activity of probiotic on carrageenan-induced paw edema in Wistar rats," *International Journal of Biological Macromolecules*, vol. 72, pp. 1277–1282, 2015.
- [42] E. Banki, Z. Hajna, A. Kemeny et al., "The selective PAC1 receptor agonist maxadilan inhibits neurogenic vasodilation and edema formation in the mouse skin," *Neuropharmacology*, vol. 85, pp. 538–547, 2014.
- [43] R. K. Singh, Vaishali, S. K. Panda et al., "Evaluation of anti-inflammatory potential of *Nardostachys jatamansi* rhizome in experimental rodents," *Journal of Coastal Life Medicine*, vol. 2, no. 1, pp. 38–43, 2014.
- [44] R. Patil, P. Langade, P. Dighade, and Y. Hiray, "Antinociceptive activity of acute and chronic administration of *Murraya koenigii* L. leaves in experimental animal models," *Indian Journal of Pharmacology*, vol. 44, no. 1, pp. 15–19, 2012.
- [45] N. Sengar, A. Joshi, S. K. Prasad, and S. Hemalatha, "Anti-inflammatory, analgesic and anti-pyretic activities of standardized root extract of *Jasminum sambac*," *Journal of Ethnopharmacology*, vol. 160, pp. 140–148, 2015.
- [46] A. L. Ogundajo, L. A. Adeniran, and A. O. Ashafa, "Medicinal properties of *Ocotea bullata* stem bark extracts: phytochemical constituents, antioxidant and anti-inflammatory activity, cytotoxicity and inhibition of carbohydrate-metabolizing enzymes," *Journal of Integrative Medicine*, vol. 16, no. 2, pp. 132–140, 2018.
- [47] G. I. Anuja, P. G. Latha, V. J. Shine et al., "Antioedematous and analgesic properties of fertile fronds of *Drynaria quercifolia*," *ISRN Inflammation*, vol. 2014, Article ID 302089, 8 pages, 2014.
- [48] T. C. Akunne, P. A. Akah, I. A. Nwabunike et al., "Anti-inflammatory and anticancer activities of extract and fractions of *Rhipsalisneves-armondii* (Cactaceae) aerial parts," *Cogent Biology*, vol. 2, no. 1, pp. 1–11, 2016.
- [49] M. Ali, M. C. Sansthan, S. Parvej, and R. Kumar, "Immunomodulatory effect of *Withania somnifera* (ashwagandha) on cyclophosphamide induced toxicity in rats," *American Journal of PharmTech Research*, vol. 5, no. 3, pp. 638–645, 2015.
- [50] J. Nfambi, G. S. Bbosa, L. F. Sembajwe, J. Gakunga, and J. N. Kasolo, "Immunomodulatory activity of methanolic leaf extract of *Moringa oleifera* in Wistar albino rats," *Journal of Basic and Clinical Physiology and Pharmacology*, vol. 26, no. 6, pp. 603–611, 2015.
- [51] K. J. Donald and A. W. Pound, "Proliferation and migration of reticuloendothelial cells following injection of a tubercle bacillary lipid," *British Journal of Experimental Pathology*, vol. 54, p. 79, 1973.
- [52] H. Sadeghi, S. Hosseinzadeh, M. A. Touri, M. Ghavamzadeh, and M. J. Barmak, "Hepatoprotective effect of *Rosa canina* fruit extract against carbon tetrachloride induced hepatotoxicity in rat," *Avicenna Journal of Phytomedicine*, vol. 6, no. 2, pp. 181–188, 2016.